Skip to main content

Table 8 Association of PD-L1 staining with estrogen receptor/progesterone receptor-positive and triple-negative status in sTIL subgroups in patients with neoadjuvant chemotherapy

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

sTIL < 10%sTIL ≥10%sTIL < 10%sTIL ≥10%sTIL < 10%sTIL ≥10%
ER/PR pos77013370296702105
Fisher P value0.00680.43310.00010.46610.00061
  1. ER estrogen receptor, PR progesterone receptor, TNBC triple-negative breast cancer, sTIL stromal tumor infiltrating lymphocytes, pos positive, neg negative